LOS ANGELES, May 12, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Ocwen Financial Corporation (“Ocwen” or the “Company”) (NYSE:OCN) concerning possible violations of federal securities laws between May 11, 2015 and April 19, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to June 20, 2017, the lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The Complaint alleges that during the Class Period, Ocwen made false and/or misleading statements and/or failed to disclose: that the Company engaged in significant and systemic misconduct at almost every stage of the mortgage servicing process; that this conduct would subject Ocwen to heightened regulatory scrutiny and potential criminal sanctions; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On April 20, 2017, the U.S. Consumer Financial Protection Bureau announced that it was suing Ocwen, and several states issued cease-and-desist orders against the Company. Following this news, Ocwen’s stock price declined materially, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



